Transarterial chemoembolization for huge XXXX with diameter over ten centimeters: a large cohort study.

@entity1 @entity788 @entity96 @entity5 @entity879 @entity1150 @entity160 @entity2679 @entity751 @entity157 @entity360 @entity2849
UNASSIGNED: @entity1 with huge @entity157 >10  cm in diameter represent a special subgroup for treatment. To date, there are few data and little consensus on treatment strategies for huge @entity157 . In this study, we summarized the effects and safety of transarterial chemoembolization for huge @entity157 . A retrospective study was performed based on a large cohort of @entity1 (n  =  511) with huge @entity157 who underwent serial transarterial chemoembolization between January 2008 to December 2011 and were followed up until March 2013. We found median survival time was 6.5  months. On multivariate analysis, @entity1 -Pugh class (A versus B) (p  <  0.0001), @entity160 ( <=400    g/L) (p  =  0.002), Barcelona Clinic @entity96 stage (B versus C) (p  =  0.013), and other treatments after transarterial chemoembolization such as surgical resection (p  =  0.008), radiation (p  =  0.018), and local radiofrequency ablation (p  =  0.002) were factors significantly associated with better  overall @entity1 survival after chemoembolization. Twenty-nine percent of these @entity1 showed a @entity5 response after serial transarterial chemoembolization. Severe complications were few (4.9  %), including @entity751 (n  =  3), @entity5 rupture (n  =  3), @entity360 (n  =  4), @entity1150 (n  =  3), acute @entity2679 (n  =  4), femoral @entity2849 (n  =  1), acute @entity788 (n  =  1), and @entity879 (n  =  6). In conclusion, transarterial chemoembolization is a safe and effective treatment for selected @entity1 with huge @entity157 and is recommended as a component of combination therapy. In addition, @entity1 with good liver function and low @entity160 levels may acquire greater survival benefits from transarterial chemoembolization.
